


### AMENDMENT TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

#### In the Claims:

1. (Original) A pharmaceutical composition for improving brain functions comprising a triterpene compound represented by the Formula 1 as an active ingredient:


[Formula 1]



wherein  $R_1$ ,  $R_2$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_3$  is H;  $R_1$  and  $R_2$  are independently  $\text{CH}_3$ ,  $R_3$  is H and  $R_4$  is  $\text{CH}_2\text{OH}$ ; or  $R_1$ ,  $R_3$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_2$  is H; and a pharmaceutically acceptable carrier or excipient.

2. (Currently amended) ~~An agent for improving brain functions;~~ A pharmaceutical composition for treating mild cognitive impairment and dementia which comprises as an active ingredient a triterpene compound represented by the Formula 1: ~~control~~

[Formula 1]



wherein  $R_1$ ,  $R_2$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_3$  is H;  $R_1$  and  $R_2$  are independently  $\text{CH}_3$ ,  $R_3$  is H and  $R_4$  is  $\text{CH}_2\text{OH}$ ; or  $R_1$ ,  $R_3$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_2$  is H; and a pharmaceutically acceptable carrier or excipient.

3-5. (Cancelled)

6. (New) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a mixture of lactose, crystalline cellulose and magnesium stearate.

7. (New) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a mixture of mannitol,  $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$  and distilled water.


8. (New) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a mixture of ginseng extract, green tea extract, vitamin C, vitamin E, ferrous lactate, zinc oxide, nicotinic amide, vitamin A, vitamin B<sub>1</sub>, vitamin B<sub>2</sub>, corn starch and magnesium stearate.

9. (New) The pharmaceutical composition of claim 2, wherein the triterpene compound is hederagenin.

10. (New) The pharmaceutical composition of claim 2, wherein the triterpene compound represented by the Formula 1 is a mixture of oleanolic acid, hederagenin and ursolic acid.

11. (New) A method of improving brain function which comprises administering to a patient in need thereof a pharmaceutical composition comprising a triterpene compound represented by the Formula 1 as an active ingredient:


[Formula 1]



wherein  $R_1$ ,  $R_2$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_3$  is H;  $R_1$  and  $R_2$  are independently  $\text{CH}_3$ ,  $R_3$  is H and  $R_4$  is  $\text{CH}_2\text{OH}$ ; or  $R_1$ ,  $R_3$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_2$  is H; and a pharmaceutically acceptable carrier or excipient.

12. (New) The method of treating mild cognitive impairment and dementia which comprises administering to a patient in need thereof a pharmaceutical composition comprising a triterpene compound represented by the Formula 1 as an active ingredient:

[Formula 1]



wherein  $R_1$ ,  $R_2$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_3$  is H;  $R_1$  and  $R_2$  are independently  $\text{CH}_3$ ,  $R_3$  is H and  $R_4$  is  $\text{CH}_2\text{OH}$ ; or  $R_1$ ,  $R_3$  and  $R_4$  are independently  $\text{CH}_3$  and  $R_2$  is H; and

a pharmaceutically acceptable carrier or excipient.